Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1826

Shown on this page

Current sort

Live official records

Conditions: Multiple Myeloma
Interventions: BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more

Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions: Biopsy, Pegylated SN-38 Conjugate PLX038, Computed Tomography, Biospecimen Collection; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Metastatic Malignant Neoplasm in the Lymph Nodes, Nasal Cavity Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Carcinoma, Paranasal Sinus Carcinoma, Salivary Gland Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions: Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Intensity-Modulated Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 9
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 6 more

Conditions: Obesity
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Alcohol-associated Hepatitis
Interventions: IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care; Drug · Behavioral
Lead sponsor: Samer Gawrieh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more

Conditions: Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous, Skin Cancer, Brachytherapy
Interventions: DaRT seeds; Device
Lead sponsor: Alpha Tau Medical LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 10
States / cities: Gilbert, Arizona • Phoenix, Arizona • Boca Raton, Florida + 6 more

Conditions: Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
Interventions: Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2041
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more

Conditions: Pancreas Cancer
Interventions: IORT; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 6
States / cities: Irvine, California • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Non-small Cell Lung Cancer
Interventions: SBRT, First or second-line standard of care therapy; Radiation · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 71
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 55 more

Conditions: Stress
Interventions: Kavalactones, Placebo; Dietary Supplement · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Conventional Chondrosarcoma
Interventions: INBRX-109, Placebo; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Beverly Hills, California • San Francisco, California + 26 more

Conditions: Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Interventions: mirvetuximab soravtansine (MIRV; IMGN853); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Live official records

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

A Study of a Novel Precision Medicine Approach For Obesity

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

A Study of Oral Kavalactones Effect on Nurses

Study of INBRX-109 in Conventional Chondrosarcoma

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

About this Mayo Clinic institution page